Tag: Health

Eyexora Establishes Co-Headquarters in Singapore to Accelerate Growth Across Asia-Pacific

by jezzabellemente, posted in Uncategorized

SINGAPORE, Nov 6 (Bernama-BUSINESS WIRE) — Eyexora, a biotech company pioneering innovative therapies for ophthalmic diseases through a hub-and-spoke model, today announced the establishment of its co-headquarters in Singapore, marking a major milestone in the company’s global expansion and deepening its commitment to advancing eye health worldwide. Eyexora’s seed financing was led by ClavystBio, a global life sciences investor based in Singapore, and its initial programs have been in-licensed from the Singapore Eye Research Institute (SERI).

The new Singapore headquarters will serve as a gateway to Eyexora’s growing activities across the Asia-Pacific region, supporting clinical development, research collaborations, and regional partnerships. This expansion further strengthens Eyexora’s collaboration with the Singapore Eye Research Institute (SERI), a long-standing partner in ophthalmic innovation.

Eyexora’s Singapore operations will be instrumental in driving the company’s mission to develop transformative, accessible treatments for patients with vision-threatening diseases, while advancing scientific collaboration in one of the world’s most dynamic healthcare innovation hubs.

“Singapore has become a global center for ophthalmic research and innovation, and we are proud to deepen our presence here,” said Theresa Heah, M.D., M.B.A., Chief Executive Officer and Vice Chair of the Board, Eyexora. “This new co-headquarters positions Eyexora at the heart of Asia-Pacific’s biomedical ecosystem and strengthens our collaboration with SERI. Together, we are accelerating the development of breakthrough therapies that can improve vision and quality of life for patients around the world.”

“This milestone reflects our vision to build a truly global ophthalmic company,” said William J. Link, Ph.D, Chairman of the Board at Eyexora. “Singapore’s strong research infrastructure and commitment to innovation make it an ideal base for expanding Eyexora’s partnerships and advancing the next generation of eye care solutions.”

“Eyexora’s new co-headquarters are a testament to Singapore’s leadership in ophthalmology research and clinical delivery, and position as a global life sciences hub,” said Khoo Shih, Ph.D, CEO, ClavystBio. “At ClavystBio, we are excited to partner seasoned leaders like Theresa, William and their team to accelerate meaningful innovations and make global health impact.”

Last month Eyexora announced the launch of its second spoke company, Y.ora Vision, Inc., focused on developing next-generation ophthalmic medical devices for glaucoma. The company’s creation, complementing initial spoke company, Serenora Therapeutics, Inc., underscores Eyexora’s commitment to building a global ecosystem of specialized ventures that advance innovation across key therapeutic areas in ophthalmology.

Eyexora’s Singapore co-headquarters complements its U.S. base in New York, and will anchor the company’s Asia-Pacific operations, including clinical, scientific, and strategic functions, as it continues to grow its global footprint.

About Eyexora

Eyexora is a global ophthalmology company pioneering a hub-and-spoke model to accelerate innovation in eye care. By centralizing scientific, clinical, regulatory, and commercial expertise, Eyexora advances a diversified pipeline of therapies and devices through focused subsidiaries, to reduce risk, improve efficiency, and scale impact. Founded by leaders with decades of ophthalmology experience and a track record of more than 30 successful company and product launches, Eyexora partners with clinician-scientists and research institutes worldwide to bring transformative eye care solutions to patients faster and smarter. For more information, visit www.eyexora.com.

About ClavystBio

ClavystBio is a life sciences investor and venture builder established by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with founders and entrepreneurs to launch and grow global companies from Asia. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing startups together, we foster a vibrant and supportive community. For more information, please visit https://www.clavystbio.com/ and follow us on LinkedIn.

About Singapore Eye Research Institute (SERI)

Established in 1997, SERI is Singapore’s national research institute for ophthalmic and vision research. SERI’s mission is to conduct high-impact eye research that prevents blindness, low vision, and major eye diseases common to Singaporeans and Asians. Over the last decade, SERI has conducted landmark research projects that have led to tangible outcomes, patient benefits, and success stories. It has paved the way for significant improvements in how eye diseases are treated and prevented, not just for Singaporeans or Asians, but on a global scale.

At its inception, SERI saw a national remit in ophthalmic and vision research, and till today, SERI ensures that its facilities and resources are open to researchers across Singapore so that the greatest benefit may be obtained from what is a relatively small clinical ophthalmology catchment area in Singapore.

SERI has grown from a founding team of five in 1997 to a faculty of more than 253 staff, encompassing clinician scientists, scientists, research fellows, PhD students and support staff. This makes SERI one of the largest research institutes in Singapore, as well as the largest eye research institute in the Asia Pacific region. SERI has also over 255 adjunct faculties from various eye departments, biomedical institutes, and tertiary centres in Singapore. SERI has published an impressive array of 5,942 scientific papers and has secured external peer-reviewed competitive grants worth more than $473 million. As of December 2024, SERI’s faculty has been awarded with more than 1,425 national and international prizes and filed 188 patents.

As the research institute of the SNEC, and directly affiliated to the Yong Loo Lin School of Medicine, National University of Singapore, as well as the Duke-NUS Medical School, SERI undertakes vision research in collaboration with local clinical ophthalmic centres and biomedical research institutions, as well as major eye centres and research institutes throughout the world.

SERI ranks first globally in terms of eye publications per capita, far ahead of the US, UK, and Japan. With its impressive publication track record, SERI is comparable to renowned eye institutes, both regionally and internationally. Please see www.seri.com.sg.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20251104717799/en/

Contact

Media Contact
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source : Eyexora

SOUNDHEALTH TO SHOWCASE AI-POWERED AIRWAY SCREENING APP AT WORLD SLEEP 2025

by jezzabellemente, posted in Uncategorized

KUALA LUMPUR, Sept 19 (Bernama) — SoundHealth, a medical technology company specialising in artificial intelligence (AI) solutions for respiratory health, will debut its groundbreaking AI-powered mobile platform, Airway, at World Sleep 2025 in Singapore this September.

The smartphone-based tool is designed to screen for obstructive sleep apnoea and sleep-disordered breathing in both children and adults. The presentation will be delivered by a team of physicians and experts, including SoundHealth founder and chief executive officer, Paramesh Gopi.

“We believe the Airway app represents a significant breakthrough in accessible airway diagnostics. By putting a non-invasive, accurate screening tool directly into the hands of clinicians and patients, we are entering a new frontier in digital health,” he said in a statement.

Meanwhile, orthodontics and dental sleep medicine expert Dr Eric Phelps said the technology could transform early detection of airway and sleep-breathing disorders, while the app provides a safe, scalable and objective tool to screen patients across all ages, expanding access to diagnosis beyond traditional clinical settings.

Airway is described as the first mobile platform that enables accurate sinonasal and airway function assessment without relying on traditional imaging methods such as cone beam computed tomography (CBCT).

The application leverages a smartphone’s camera and microphone to provide a non-invasive and radiation-free solution for large-scale screening.

The system works by capturing 3D facial scans to extract craniofacial landmarks predictive of nasal dimensions, allowing for a virtual reconstruction of airway structures, and also analyses voice recordings to measure speech resonance in different positions, producing a “Voice Nasal Flow Index” sensitive to posture-related congestion and obstruction.

According to validation studies, the platform demonstrated 95 per cent accuracy when compared with clinical CT scans for key nasal airway parameters. It generates three main scores—upper airway susceptibility, lower airway resistance and the Voice Nasal Flow Index—combined into an overall “Airway Health Score”.

The app is designed for scalable use in schools, dental practices and sleep clinics, offering early detection of airway dysfunctions that may affect craniofacial development, orthodontic planning and sleep quality.

— BERNAMA

KFSHRC Saves Saudi 7-Year-Old Through Cross-Border Heart Transplant with UAE Donor Organ

by jezzabellemente, posted in Uncategorized

RIYADH, Saudi Arabia, Aug 22 (Bernama-GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has successfully performed a life-saving heart transplant on a 7-year-old Saudi child using an organ donated by a brain-dead donor in Abu Dhabi, United Arab Emirates.

The complex procedure was made possible through seamless cross-border cooperation between the Saudi Center for Organ Transplantation and the UAE’s National Program for Donation and Transplantation of Human Organs and Tissue (HAYAT), with full consent from the donor’s family and all regulatory approvals in place.

This cooperation involved precise medical and logistical coordination, starting with the organ extraction, followed by air transportation to Riyadh, and concluding with the preparation of operating theaters in record time. The transplantation was performed within a critically time-sensitive window, ultimately saving the life of a child who had no other treatment options available.

The medical team at KFSHRC performed the transplantation on the child, who was suffering from advanced heart failure due to a complex congenital heart defect. After exhausting all available treatment options—including medications, respiratory support, and pacemaker implantation—without any significant improvement, the child was placed on the urgent transplant list.

Time is a critical factor in heart transplant operations. According to medical standards, the period between removing the heart from the donor and transplanting it into the patient must not exceed five hours to ensure transplant success. This time constraint creates significant logistical challenges in addition to the complex medical procedures, particularly when the brain-dead donor is located in another region within the Kingdom or overseas. In such circumstances, every minute of delay becomes crucial to the operation’s success.

The KFSHRC Heart Centre is recognized as one of the world’s leading cardiac centers, having achieved exceptional milestones including the world’s first fully robotic heart transplant and robotic artificial heart pump implantation without chest incision. These unprecedented medical breakthroughs demonstrate the Kingdom’s leadership in complex cardiac surgery.

KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world’s top 250 Academic Medical Centers for the second consecutive year and has been recognized as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. It was included in the world’s best 250 hospitals and in the World’s Best Smart Hospitals list for 2025 by Newsweek magazine.

For more information, visit http://www.kfshrc.edu.sa or contact our media team at mediacoverage@kfshrc.edu.sa

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/aaf4d900-7f18-4871-9809-29e19875c14a

SOURCE: King Faisal Specialist Hospital & Research Centre

Invisalign® Palatal Expander System by Align Technology Now Available in Malaysia for Skeletal and Dental Expansion in Growing Patients

by jezzabellemente, posted in Uncategorized
Photo: Patient independently inserting Invisalign® Palatal Expander.

· Invisalign® Palatal Expanders offer doctors an effective and easily removeable alternative to traditional palatal expanders, without the need for metal and screws.
· Combined with Invisalign First™ aligners, Invisalign Palatal Expanders provide doctors with a full early intervention treatment solution, including both skeletal (orthopedic) and dental (orthodontic) arch expansion.

KUALA LUMPUR, Malaysia, July 23 (Bernama-BUSINESS WIRE) — Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that Align’s Invisalign Palatal Expander System* has been notified as Class B medical device by Malaysia Medical Device Authority and is now commercially available in Malaysia for broad patient applicability, including growing children, teens and adults (with surgery or other techniques).

This press release features multimedia. View the full release here: 
https://www.businesswire.com/news/home/20250722815570/en/

The Invisalign Palatal Expander System* is a modern and innovative direct 3D printed device based on proprietary and patented technology. Invisalign Palatal Expanders are intended for use in rapid expansion and subsequent holding of skeletal and/or dental narrow maxilla (upper jaw) with primary, mixed, or permanent dentition during treatment of patients.

“The Invisalign Palatal Expander System* exemplifies our commitment to advancing digital orthodontics with innovative solutions that enhance patient treatment experiences,” said David Carr, Align Technology executive vice president and managing director, Asia Pacific. “We are excited to extend the availability of the transformative Invisalign Palatal Expander system, Align’s first direct 3D printed orthodontic appliance, to even more doctors and their patients markets across the Asia Pacific region.”

The Invisalign Palatal Expander System* consists of a series of removable devices staged in small increments of movement to expand a patient’s narrow maxilla to a position determined by their treating doctor. Each direct 3D printed device is customized to the patient’s unique anatomy based on an iTero™ intraoral digital scan. A palatal expansion treatment plan and device design are then developed using Align’s proprietary AI-driven orthodontic software.

Combined with Invisalign First™ aligners, Invisalign Palatal Expanders provide doctors with a full early intervention treatment solution for Phase 1 treatment, an early interceptive orthodontic treatment for young patients. Phase 1 treatment is traditionally done through arch expanders or partial metal braces, before all permanent teeth have erupted – typically at ages 6 through 10. Invisalign First clear aligners are designed specifically to address a broad range of younger patients’ malocclusions, including shorter clinical crowns, management of erupting dentition, and predictable dental arch expansion.

“Phase 1 or early interceptive treatment accounts for 20 percent of orthodontic case starts each year and is growing,” said Dr. Mitra Derakhshan, Align Technology executive vice president, chief clinical officer, global treatment planning and clinical services. “Together with Invisalign First aligners, Invisalign Palatal Expanders provide doctors with a solution set to treat the most common skeletal and dental malocclusions in growing children. The addition of mandibular advancement features to Invisalign aligners also provides doctors with more options for treating skeletal and dental jaw imbalances and bite correction for their growing patients during their teenage years.”

The Invisalign Palatal Expander System* is available in Australia, New Zealand, Hong Kong, Singapore, Vietnam, Japan, Thailand, India and Malaysia.

* Children shall not use device without supervision.

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® System, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and is key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat approximately 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align Digital Platform™, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.

For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit www.invisalign.com.my For additional information about the iTero digital scanning system, please visit www.itero.com/en-APAC. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.

Invisalign, iTero, exocad, Align, and Align Digital Platform are trademarks of Align Technology, Inc.

About the Invisalign Palatal Expander System

The Invisalign Palatal Expander System is a modern, innovative direct 3D printed orthodontic appliance designed based on proprietary and patented technology. The Invisalign Palatal Expander System is intended for the orthodontic treatment of malocclusion. The system is used for the rapid expansion and subsequent holding of skeletal and/or dental narrow maxilla (upper jaw, dental arch and teeth, palate) with primary, mixed, or permanent dentition during orthopedic treatment in children or adolescents. In adults, it is to be used in conjunction with surgery or other interventions when necessary. Devices are 3D printed and are manufactured based on digital scan data from commercially available iTero™ intraoral scanners offered by Align Technology, Ltd. The devices are removable for proper oral hygiene; manufactured to custom fit each patient’s anatomy for optimal comfort and aesthetics, expanders fit comfortably in the patient’s mouth and are changed daily (no screw required).

The System is comprised of Invisalign Palatal Expanders (active expansion, each stage comes with a programmed expansion of up to 0.25mm/stage, changed daily or as per doctor’s discretion) and Invisalign Palatal Holders (copies of the last stage ​of the expansion phase designed to hold the maxilla post-active expansion and changed every 2-4 weeks as directed by the treating doctor), Invisalign Attachment Templates and proprietary 3D shape generation software. These products are not available for purchase by the general public. However, the products are available for purchase from Invisalign® trained dentists and orthodontists.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20250722815570/en/

Contact

Align Technology
Madelyn Valente
(909) 833-5839
mvalente@aligntech.com

Zeno Group
Sarah Johnson
(828) 551-4201
sarah.johnson@zenogroup.com

Source : Align Technology, Inc.

–BERNAMA

Spring Bio Solution Launches NCE Grid to decode Para IV Filing and First-to-File Opportunities

by jezzabellemente, posted in Uncategorized

SOMERSET, N.J., June 12 (Bernama-GLOBE NEWSWIRE) — Spring Bio Solution, a global leader in the comparator sourcing and clinical trial supplies, has launched NCE Grid, the world’s first free NCE-1 intelligence platform – built to decode, centralize, and visualize Para IV and NCE-1 opportunities in real-time.

Until now, tracking NCE exclusivity expirations and Paragraph IV filings has been a fragmented, manual, and cumbersome process, lacking a centralized solution. Regulatory updates are scattered across various portals, intelligence is buried in siloed databases, and timelines are tracked using spreadsheets. The result? Competitive blind spots, misaligned R&D, and a race already lost before it begins.

For generic pharmaceutical companies aiming to be the “first to file,” intelligence gaps, scattered data, and missed timelines can result in lost exclusivity and millions in revenue.

NCE Grid changes that.

NCE Grid is the world’s first free tool to integrate every critical data point, including molecule, innovator name, NCE-1 date, revenue, therapeutic usage, expected sales growth, and CAGR% into one intuitive platform. With real-time visualizations and actionable insights, NCE Grid empowers strategy, regulatory, and portfolio teams to identify, prioritize, and act on first-to-file opportunities with clarity and speed.

“We created NCE Grid because we saw too many companies struggle with fragmented insights and missed opportunities,” said Salim Shaikh, Founder and CEO of Spring Bio Solution. “In a race where timing is everything, our platform brings clarity, speed, and a competitive edge to decision-makers. When you think Para IV, think NCE Grid — Your trusted guide for strategic drug development.” 

To learn more, visithttps://ncegrid.springbiosolution.com/

About Spring Bio Solution

Spring Bio Solution partners with CROs, pharmaceutical companies, and research institutions worldwide, offering reliable solutions for comparator sourcing and clinical trial supplies. With offices and WDL (wholesale Drug Distribution License) facilities across the USA, EU, Singapore, and India, and a robust network of 400+ distribution partners and 30+ innovators, Spring Bio Solution ensures timely and compliant access to critical drug supplies.

Trusted by over 600 clients and maintaining a 99.9% success rate for sourcing comparator drugs/ RLDs/ innovator samples, the company offers industry-leading cold chain capabilities, ranging from -60°C to ambient temperatures. Through its partnership with LSPedia, Spring Bio Solution also ensures full DSCSA compliance and end-to-end traceability.

With experience supporting over 1,000 clinical trials and more than 12,000 bioequivalence studies, Spring Bio Solution empowers sponsors to de-risk operations and accelerate drug development with confidence.

For media inquiries, please contact:

Navdeep Trivedi
Vice President & Head, Digital Marketing
Spring Bio Solution
navdeep.trivedi@springbiosolution.com

SOURCE: Spring Bio Solution PTE.LTD